Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Nabriva Therapeutics AG - ADR    NBRV

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
10.84(c) 10.76(c) 11.04(c) 10.99(c) 10.89(c) Last
6 321 7 776 9 511 8 123 29 646 Volume
-1.28% -0.74% +2.60% -0.45% -0.91% Change
More quotes
Financials ($)
Sales 2017 6,09 M
EBIT 2017 -61,9 M
Net income 2017 -66,8 M
Finance 2017 155 M
Yield 2017 -
Sales 2018 5,92 M
EBIT 2018 -76,9 M
Net income 2018 -81,3 M
Debt 2018 21,5 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 23,1x
EV / Sales2018 53,7x
Capitalization 296 M
More Financials
Company
Nabriva Therapeutics AG is a clinical-stage biopharmaceutical company.It engages in the research and development of novel antibiotics to treat infections, with a focus on the pleuromutilin class of antibiotics.The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna,... 
More about the company
Surperformance© ratings of Nabriva Therapeutics AG -
Trading Rating : Investor Rating :
More Ratings
Latest news on NABRIVA THERAPEUTICS AG -
04/19 Nabriva Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care ..
04/18 NABRIVA THERAPEUTICS AG : Other Events, Financial Statements and Exhibits (form ..
04/18 NABRIVA THERAPEUTICS : Announces the Proposed Redomicile of its Holding Company ..
04/17 Nabriva Announces the Proposed Redomicile of its Holding Company from Austria..
04/14 INSIDER TRADING ACTIVITY NABRIVA THE : NBRV) – Ca (Major Shareholder Sold ..
04/14 NABRIVA THERAPEUTICS : to present data at ECCMID supporting ongoing Phase 3 clin..
04/13 Nabriva Therapeutics to present data at ECCMID supporting ongoing Phase 3 cli..
04/11 Nabriva Therapeutics Announces Enrollment Completion for LEAP 1, a Phase 3 Cl..
04/11 INSIDER TRADING ACTIVITY NABRIVA THE : NBRV) – Ca (Major Shareholder Sold ..
04/05 NABRIVA THERAPEUTICS AG : Regulation FD Disclosure, Financial Statements and Exh..
More news
Sector news : Biotechnology & Medical Research - NEC
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
04/26 The Antimicrobial Resistance Crisis
04/17 Why Investors Are Bullish On Nabriva
04/17 Is There More Upside? Edition 1
04/11 INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Plse, apo, glo, glq, opk
04/05 Nabriva Therapeutics (NRV) Investor Presentation - Slideshow
Advertisement
Chart NABRIVA THERAPEUTICS AG -
Duration : Period :
Nabriva Therapeutics AG -  Technical Analysis Chart | NBRV | US62957M1045 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 16,4 $
Spread / Average Target 51%
Consensus details
Managers
NameTitle
Colin Broom Chief Executive Officer
Daniel D. Burgess Chairman-Supervisory Board
Gary L. Sender Chief Financial Officer
Elyse G. Seltzer Chief Medical Officer
Thomas Lembck Chief Information Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NABRIVA THERAPEUTICS A..82.72%296
INCYTE CORPORATION23.95%25 426
QUINTILES IMS HOLDINGS..10.82%19 884
LONZA GROUP AG17.13%11 836
SEATTLE GENETICS, INC.29.43%9 741
CELLTRION, INC.--.--%9 653
More Results